Although PD-L1 and TMB are well-established predictive biomarkers in non-small cell lung cancer (NSCLC), their clinical utility in SCLC remains limited because of low PD-L1 expression, methodological heterogeneity, and restricted tissue availability. The gene discussed is CD274; the disease is small cell lung carcinoma.